宜章哪里算命的比较好(铜山哪儿算命准) (今日更新中)

PARIS, Oct. 1 (Xinhua) -- People come to the French capital will be able to enjoy a new public service by leasing electric cars in the urban region from Sunday.This car-sharing system is aimed to reduce the number of private cars as well as restrain pollution, according to the Paris municipal government.The plan, dubbed "the Autolib" system, is similar to already functioning "velib system" which is a large-scale public bicycle sharing system in Paris launched in 2007.The first experimental stage of the Autolib project is said to last two month with 66 cars at 33 stations around the city.Costumers can pay between 5 euros and 7 euros (6.7-9.4 U.S. dollars) for every half-hour use or register for a yearly, weekly or 24-hour package with different cost and necessary identity cards, driving licences and an uncashed deposit.Once fully charged, the four-seated "Bluecar" can reach a top speed of 130 km an hour and has a range of 250 km with a single charge.In order to encourage short journey rather than long trip around the capital, Paris administration wants to expand the system to a 250-car team by this December, and then to 2,000 by next summer.

BEIJING, Jan. 24 (Xinhua) -- Chinese President Hu Jintao and Premier Wen Jiabao on Tuesday exchanged congratulatory messages with their Israeli counterparts Shimon Peres and Benjamin Netanyahu on the 20th anniversary of the establishment of diplomatic ties between the two countries.Hu said the friendly exchanges between the Chinese and the Jewish people go back to ancient times.Since the forging of official ties 20 years ago, friendly cooperative ties between China and Israel have been developing continuously, and the exchanges and cooperation between the two sides in politics, economy and trade, culture, science and technology, agriculture and education have yielded fruitful results and brought tangible benefits to the two countries and the two peoples, Hu said.China attaches great importance to advancing Sino-Israeli ties and is ready to make joint efforts with Israel to take the celebration of the 20th anniversary as an opportunity to further consolidate the traditional Sino-Israeli friendship, deepen mutual cooperation in various fields, increase personnel exchanges on multiple levels, and promote a continuous development of friendly Sino-Israeli cooperative relations, he said.For his part, Peres said Israel and China established official diplomatic ties 20 years ago, which brought the friendship between the two countries to a historic high.He believed that the Israeli-Chinese friendship, which is based on a shared history, common values and ancient culture and tradition, will prevail.Peres said his country pays great attention to its ties with China in all areas, and is willing to conduct mutually beneficial cooperation with China in science and technology and other fields.In his message, Peres wished the Chinese people a "Happy New Year" in the Year of the Dragon.On the same day, Chinese Premier Wen also exchanged congratulatory messages with Israeli Prime Minister Netanyahu.Wen said their bilateral friendly cooperative relations have continued to grow over the last 20 years.Political exchanges between the two countries have been increasingly close, economic and trade cooperation have continued to flourish, and pragmatic cooperation in culture, science and technology, and agriculture has been fruitful, Wen said.China and Israel have their own advantages, as well as huge potential and broad prospects for cooperation, the Chinese premier said.China is ready to continue to expand and deepen its friendly bilateral cooperation with Israel and raise Sino-Israeli ties to a new high, Wen said.For his part, Netanyahu said the Chinese and the Jewish people have always been friends.During the past 20 years, China and Israel succeeded in forging a stable and diversified partnership, he said.The Israeli side is ready to fully explore the potential of bilateral ties and continue to expand cooperation in science and technology, sanitation, agriculture and environmental protection technologies and other fields with China, Netanyahu said.He believed that there will be more opportunities to further consolidate the friendship between the two peoples and deepen bilateral cooperation in the future.Chinese Foreign Minister Yang Jiechi and Israeli Foreign Minister Avigdor Lieberman also exchanged congratulatory messages.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

WASHINGTON, Oct. 3 (Xinhua) -- Researchers at St. Michael's Hospital in Canada have discovered a new function for an enzyme that may protect against organ injury and death from anemia, according to a study appearing Monday in the U.S. journal of the Proceeding of the National Academy of Sciences.Researchers found that when people have anemia, neuronal nitric oxide synthase (nNOS) -- an enzyme in nerve cells that produces nitric oxide, an important signaling molecule in the body -- increases the body's ability to respond, adapt to low oxygen levels and makes the body more efficient in delivering oxygen to tissues. They also found that levels of nNOS in the brain increased in anemic mice, and that the mice without this enzyme die earlier, and with higher hemoglobin levels."Identifying this mechanism may lead to new therapies and approaches to improving outcomes for anemic patients," said Dr. Greg Hare, a researcher at the Li Ka Shing Knowledge Institute of the hospital and one of the lead investigators of the study.Anemia occurs when blood has a lower than normal number of red blood cells or hemoglobin -- an iron-rich protein that carries oxygen from the lungs and heart to the rest of the body. Cells need oxygen to survive and to produce energy for all bodily functions. The condition has many different causes including infection (malaria, HIV, parasites), nutritional deficiencies (iron, folate, B12), genetic mutations, pregnancy, trauma and surgical blood loss."This research will help us identify when an anemic patient is at greatest risk for injury and death when undergoing surgery," said Hare. "Research is underway to test these findings in humans."

SAN FRANCISCO, Nov. 14 (Xinhua) -- Google is running a secret research lab in the San Francisco Bay Area, where the tech giant invests to experiment and invent what may be world-changing technologies for the future, U.S. media reported on Monday.According to The New York Times, at the lab dubbed Google X, engineers are working at some 100 projects from robots, smart refrigerators to Internet-enabled dinner plates and a "space elevator," a proposed non-rocket space launch structure.An unnamed Google engineer familiar with the lab told the newspaper that it was run as mysteriously as the CIA with two officers, a nondescript one for logistics on the company's Mountain View campus and one for robots in a secret location.Scientists working at the lab include many roboticists and electrical engineers hired from Microsoft, Nokia labs, Stanford, MIT, Carnegie Mellon and New York University. Google's co-founder Sergey Brin is said to be "deeply involved" in Google X.The lab is reportedly headed by Sebastian Thrun, one of the world's top robotics and artificial intelligence experts. He teaches computer science at Stanford University and invented the world's first self-driving car.A Google spokeswoman would not confirm the existence of the lab, but said Google likes to invest in speculative projects."While the possibilities are incredibly exciting, please do keep in mind that the sums involved are very small by comparison to the investments we make in our core businesses," she told The New York Times.

来源：资阳报